Cantor Fitzgerald Reiterates Overweight on ProQR Therapeutics, Maintains $8 Price Target
Benzinga Newsdesk 1 year ago
NewsPrice TargetReiterationAnalyst Ratings
Cantor Fitzgerald analyst Timur Ivannikov reiterates ProQR Therapeutics (NASDAQ:PRQR) with a Overweight and maintains $8 price target.
Cantor Fitzgerald analyst Timur Ivannikov reiterates ProQR Therapeutics (NASDAQ:PRQR) with a Overweight and maintains $8 price target.